Driving Vaccine Development

Pfizer's mission is to deliver medicines that make a real difference in quality of life for patients with vaccines-related conditions. Scientists in our research and development (R&D) programs are committed to speeding the delivery of new treatments. We pledge to maintain the safety of patients who take part in our trials and to uphold the highest ethical standards in all of our research initiatives.

On this page, you will find more information about our pipeline, which investigational therapies are under development, and in which stages.

Vaccines Pipeline & Trials

Vaccines as of January 28, 2020

Download Complete Pipeline PDF

Discovery Projects
Phase 1

0
Phase 2

4
Phase 3

2
Registration

0
Total6

Compound Name	Indication	Phase	Submission Type	Compound Type
PF-06482077 Therapeutic Area: Vaccines Phase:Phase 3 Compound Type:Vaccine Business Segment: Biopharma Mechanism of Action: Prophylactic Vaccine Go to clinical trial	Invasive and non-invasive Pneumococcal infections (adult) (BREAKTHROUGH)	Phase 3	New Molecular Entity	Vaccine
PF-06425090 Therapeutic Area: Vaccines Phase:Phase 3 Compound Type:Vaccine Business Segment: Biopharma Mechanism of Action: Prophylactic Vaccine Go to clinical trial	Primary clostridioides difficile infection (FAST TRACK)	Phase 3	New Molecular Entity	Vaccine
PF-06928316 Therapeutic Area: Vaccines Phase:Phase 2 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine Go to clinical trial	Respiratory Syncytial Virus Infection	Phase 2	New Molecular Entity	Vaccine
PF-06886992 Therapeutic Area: Vaccines Phase:Phase 2 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine Go to clinical trial	Serogroups ABCWY meningococcal infections	Phase 2	New Molecular Entity	Vaccine
PF-06842433 Therapeutic Area: Vaccines Phase:Phase 2 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine Go to clinical trial	Invasive and non-invasive Pneumococcal infections	Phase 2	New Molecular Entity	Vaccine
PF-06760805 Therapeutic Area: Vaccines Phase:Phase 2 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine Go to clinical trial	Invasive Group B streptococcus infection	Phase 2	New Molecular Entity	Vaccine